Social Preferences for Rare Diseases in Spain

Abstract

To investigate whether early improvements in patient-reported outcomes (PROs) observed with certolizumab pegol (CZP) treatment were maintained over 4 years in the RAPID-PsA trial of patients with psoriatic arthritis (PsA). Methods: RAPID-PsA (NCT01087788) was double-blinded and placebocontrolled to Week (Wk)24, dose-blinded to Wk48 and open-label to Wk216. Patients